Pharmaceutical spheroid formulation

Details Pharmaceutical spheroid formulation Pharmaceutical spheroid formulation

1996-06-18

1997-02-11

Webman, Edward J.

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Particulate form

424461, 424469, A61K 916, A61K 962, A61K 926

Patent

active

056018452

ABSTRACT:
A controlled release composition including spheroid cores of diltiazem. or a pharmaceutically acceptable salt thereof and optionally a spheronizing agent, the cores being coated with a controlled release layer, and a method of manufacturing the same, is disclosed. The spheronizing agent when present is preferably microcrystalline cellulose. Ethylcellulose is a preferred release coating. The controlled release coating preferably contains a plasticizer, a surfactant and a tack-modifier.

REFERENCES:
patent: 4456628 (1984-06-01), Bauer et al.
patent: 4721619 (1988-01-01), Panoz et al.
patent: 4808413 (1989-02-01), Joshi
patent: 4894240 (1990-01-01), Geoghegan et al.
patent: 4917899 (1990-04-01), Geoghegan et al.
patent: 4917900 (1990-04-01), Jones et al.
patent: 4960596 (1990-10-01), Debregeas et al.
patent: 5002776 (1991-03-01), Geoghegan et al.
patent: 5112621 (1992-05-01), Stevens et al.
patent: 5219621 (1993-06-01), Geoghegan et al.
patent: 5286497 (1994-02-01), Hendrickson et al.
patent: 5364620 (1994-11-01), Geoghegan et al.
(Abstract), Pharmaceuticals, p. 8, Week K23, Abstract #54403 K/23 (EP-80-341), "Pharmaceutical multiple units formulation - with enterically coated cores for reduced peak plasma drug concentration", Benzon A AS.
(Abstract) Pharmaceuticals, Week K25, Abstract #59112 K/25 (EP-81-006), "Composition of beta-adrenergic blocer and tetra-hydro-benzazepine - useful as atihypertensive and in improving efficiency of kidney function", Alcide Co. Ltd. Partn (ALLI).
(Abstract) Pharmaceuticals, p. 3, Week 8407, Abstract #84-038350/07 (EP-100-061-A), "Pharmaceutical dosage units with enhanced bio:availability - especially hydro:chloro:thiazide-triamterene mixtures for uniform absoprtion", Mylan Pharm, Inc.
(Abstract) Pharmaceuticals, p. 6, Week 8528, Abstract #85-166500/28 (EP-147-750-A), "Pharmaceutical composition for oral, rectal or vaginal administration - with polyvinyl alcohol film coating for controlled and prolonged release", (Merck & Co., Inc.
(Abstract) No. 22342C/13 (EP-9-657), "Diuretic compositions containing potassium retaining agents - comprising 2,4-di:amino-5-aminobenzyl-pyrimidine derivatives", Hoffman-LaRoche AG.
(Abstract) No. 1593062, "Pharmaceutical controlled release compositions", 16 Sep. 1977, Richter Gedeon Vegyeszeti Gyar RT.
(Abstract), No. 85-184021/31 (EP-154-009-A), "Treatment of hypertension in patent - by administration of thiazide diuretic at level to cause antihypertensive action with diuresia", Euro-Celtique, S.A.
(Abstract), No. 89-158961/22 (EP-317-855-A), "Combination of moxonidine, hydro:chloro:thiazide and opt. triamteren - for long-term treatment of hypertonia and oedemas", Beiersdorf AG.

Affiliated with

Also associated with

Rating

Pharmaceutical spheroid formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical spheroid formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical spheroid formulation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-339899